March 1, 2007 -- Rosetta Genomics, an Israeli biotech, had the good fortune to price its long-delayed IPO on Monday night, before the 3% downdraft on Tuesday. Rosetta is seeking to develop diagnostic and therapeutic products based on genes that are known as microRNAs. MicroRNAs are naturally expressed, using instructions coded in DNA. They are thought to be important in regulating protein production, and they seem to play a significant role in cancer, which is where Rosetta is focused. We look at what Rosetta hopes to do...
